Piper Jaffray Companies Analysts Lift Earnings Estimates for NextCure Inc (NASDAQ:NXTC)

NextCure Inc (NASDAQ:NXTC) – Investment analysts at Piper Jaffray Companies lifted their Q2 2019 earnings per share (EPS) estimates for shares of NextCure in a note issued to investors on Monday, June 10th. Piper Jaffray Companies analyst E. Tenthoff now expects that the company will post earnings of ($0.30) per share for the quarter, up from their previous forecast of ($0.35). Piper Jaffray Companies has a “Overweight” rating and a $26.00 price target on the stock. Piper Jaffray Companies also issued estimates for NextCure’s Q3 2019 earnings at ($0.28) EPS, Q4 2019 earnings at ($0.29) EPS, FY2019 earnings at ($1.22) EPS, Q1 2020 earnings at ($0.29) EPS, Q2 2020 earnings at ($0.36) EPS, Q3 2020 earnings at ($0.37) EPS, Q4 2020 earnings at ($0.44) EPS and FY2020 earnings at ($1.46) EPS.

Separately, Morgan Stanley assumed coverage on shares of NextCure in a research note on Monday, June 3rd. They set an “overweight” rating and a $25.00 target price for the company.

NASDAQ NXTC opened at $14.49 on Thursday. NextCure has a 52-week low of $13.93 and a 52-week high of $22.75.

In other NextCure news, Director Stella Xu acquired 125,000 shares of the company’s stock in a transaction on Monday, May 13th. The stock was acquired at an average price of $15.00 per share, for a total transaction of $1,875,000.00. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, major shareholder X L.P. Canaan acquired 50,000 shares of the company’s stock in a transaction on Monday, May 13th. The stock was acquired at an average price of $15.00 per share, with a total value of $750,000.00. The disclosure for this purchase can be found here.

About NextCure

There is no company description available for NextCure Inc

Recommended Story: What does a dividend yield signify to investors?

Earnings History and Estimates for NextCure (NASDAQ:NXTC)

Receive News & Ratings for NextCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NextCure and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply